Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
Status:
Completed
Trial end date:
2019-07-19
Target enrollment:
Participant gender:
Summary
10 patients with chronic genotype 1 HCV infection and mixed cryoglobulinemia will be treated
with Ledipasvir/Sofosbuvir 90mg/400 mg FDC once daily for 12 weeks (naïve subjects or
non-cirrhotic treatment experienced subjects) or 24 weeks (treatment experienced subjects
with cirrhosis).
The researchers anticipate that approximately 20% of subjects may have cirrhosis.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborator:
Gilead Sciences
Treatments:
Antiviral Agents Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir